TY - JOUR
T1 - Characteristics of confirmed mpox cases among clinical suspects: a prospective single-centre study in Belgium during the 2022 outbreak
AU - ITM Monkeypox Study Group
AU - Hens, Matilde
AU - Brosius, Isabel
AU - Berens-Riha, Nicole
AU - Coppens, Jasmine
AU - Van Gestel, Liesbeth
AU - Rutgers, Jojanneke
AU - Kenyon, Chris
AU - Soentjens, Patrick
AU - van Henten, Saskia
AU - Bracke, Stefanie
AU - Vanbaelen, Thibaut
AU - Vandenhoven, Leen
AU - Bottieau, Emmanuel
AU - Vercauteren, Koen
AU - Van Esbroeck, Marjan
AU - Liesenborghs, Laurens
AU - Van Dijck, Christophe
N1 - FTX; © 2023 The Authors.; CINTEXT12 (CC BY-NC-ND 4.0)
PY - 2023
Y1 - 2023
N2 - BACKGROUND: The presentation of mpox clade IIb during the 2022 outbreak overlaps with a range of other diseases. Understanding the factors associated with mpox is important for clinical decision making.METHODS: We described the characteristics of mpox patients who sought care at Belgian sexual health clinic. Furthermore we compared their characteristics to those of patients with a clinical suspicion of mpox but who tested negative on polymerase chain reaction.RESULTS: Between May 23 and September 20, 2022, 155 patients were diagnosed with mpox, and 51 patients with suspected symptoms tested negative. All mpox patients self-identified as men and 148/155 (95.5%) as gay or bisexual MSM. Systemic symptoms were present in 116/155 (74.8%) patients. All but 10 patients (145/155, 93.5%) presented with skin lesions. Other manifestations were lymphadenopathy (72/155, 46.5%), proctitis (50/155, 32.3%), urethritis (12/155, 7.7%), tonsillitis (2/155, 1.3%). Complications involved bacterial skin infection (13/155, 8.4%) and penile oedema with or without paraphimosis (4/155, 2.6%). In multivariable logistic regression models, the presence of lymphadenopathy (OR 3.79 95% CI 1.44-11.49), skin lesions (OR 4.35 95% CI 1.15-17.57) and proctitis (OR 9.41 95% CI 2.72-47.07) were associated with the diagnosis of mpox. There were no associations with age, HIV status, childhood smallpox vaccination, number of sexual partners and international travel.CONCLUSIONS: The presence of proctitis, lymphadenopathies and skin lesions should increase clinical suspicion of mpox in patients with compatible symptoms.
AB - BACKGROUND: The presentation of mpox clade IIb during the 2022 outbreak overlaps with a range of other diseases. Understanding the factors associated with mpox is important for clinical decision making.METHODS: We described the characteristics of mpox patients who sought care at Belgian sexual health clinic. Furthermore we compared their characteristics to those of patients with a clinical suspicion of mpox but who tested negative on polymerase chain reaction.RESULTS: Between May 23 and September 20, 2022, 155 patients were diagnosed with mpox, and 51 patients with suspected symptoms tested negative. All mpox patients self-identified as men and 148/155 (95.5%) as gay or bisexual MSM. Systemic symptoms were present in 116/155 (74.8%) patients. All but 10 patients (145/155, 93.5%) presented with skin lesions. Other manifestations were lymphadenopathy (72/155, 46.5%), proctitis (50/155, 32.3%), urethritis (12/155, 7.7%), tonsillitis (2/155, 1.3%). Complications involved bacterial skin infection (13/155, 8.4%) and penile oedema with or without paraphimosis (4/155, 2.6%). In multivariable logistic regression models, the presence of lymphadenopathy (OR 3.79 95% CI 1.44-11.49), skin lesions (OR 4.35 95% CI 1.15-17.57) and proctitis (OR 9.41 95% CI 2.72-47.07) were associated with the diagnosis of mpox. There were no associations with age, HIV status, childhood smallpox vaccination, number of sexual partners and international travel.CONCLUSIONS: The presence of proctitis, lymphadenopathies and skin lesions should increase clinical suspicion of mpox in patients with compatible symptoms.
U2 - 10.1016/j.nmni.2023.101093
DO - 10.1016/j.nmni.2023.101093
M3 - A1: Web of Science-article
C2 - 36874154
SN - 2052-2975
VL - 52
SP - 101093
JO - New Microbes and New Infections
JF - New Microbes and New Infections
ER -